Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Medite Cancer Diagnostics, Inc. | c58278ae10vq.htm |
| EX-10.1 - EX-10.1 - Medite Cancer Diagnostics, Inc. | c58278aexv10w1.htm |
| EX-31 - EX-31 - Medite Cancer Diagnostics, Inc. | c58278aexv31.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, the undersigned Chief Executive Officer and Chief Financial Officer of CytoCore, Inc.
(the “Company”) certifies that, to his knowledge:
1. The Company’s Form 10-Q for the quarter ended March 31, 2010 (the “Report”) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
| /s/ Robert F. McCullough, Jr. | ||||
| Robert F. McCullough, Jr. | ||||
| Chief Executive Officer and Chief Financial Officer |
||||
| Dated: May 24, 2010 | ||||